The investment tide has shifted. Investors have recently become impatient with the stagnant and even negative performances of Brazil and China and are now moving into US stocks. India’s Sensex Index had been a beacon of light for BRIC countries in 2010, up until its abrupt reversal recently that has sent the index... Read more
Posts Tagged ‘Merck’
$20 Billion Pours Into US Funds, Emerging Markets Decline
February 17 | Posted by Kevin Monaghan | Top Story Tags: AAPL, Apple, China Mobile, CHL, Emerging Markets, ETF, EWJ, Exxon Mobil, iShares, Japan, Kraft, Merck, Microsoft, MRK, MSCI Japan Index, MSFT, QQQ, QQQQ, Stocks, US Equities, Wal-mart, WMT, XOM
Two Of The Most Attractive Discounted Stocks In The Dow
January 28 | Posted by Kevin Monaghan | Top Story Tags: AAPL, Altria, Apple, AT&T, INTC, Intel, JNJ, Johnson & Johnson, KFT, Kraft, Merck, Microsoft, MO, MSFT, PFE, Pfizer, T, Travelers, TRV, Verizon, VZI recently looked through the DOW components to start my search of where I wanted to invest my recent sales of 2010 holdings Kraft (KFT) and Altria (MO). It’s not a rule of thumb to limit my search to the DOW, I usually like to start there to get a sense of what... Read more
Are The Big Drug Companies Still Good Value?
December 13 | Posted by Kevin Monaghan | Top Story Tags: 2011 Outlook, BMY, Bristol-Myers Squibb, Crucell, CRXL, Drug Companies, GENZ, Genzme, Goldman Sachs, GS, JNJ, Johnson & Johnson, Legg Mason, LM, Merck, MRK, PFE, Pfizer, Pharmaceuticals, Sanofi-Aventis, SNY, Value, Value StocksThe Big Pharmaceutical companies have had a slow going year. Many of them are trading right where they started in 2010 or even lower. Although there have been winners such as Genzyme (GENZ), who received a bid from Sanofi-Aventis (SNY) and now trades near $70 after starting the year under $50, most of... Read more
